3,736 Shares in Moderna, Inc. (NASDAQ:MRNA) Purchased by First Trust Direct Indexing L.P.

First Trust Direct Indexing L.P. purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the fourth quarter, HoldingsChannel.com reports. The institutional investor purchased 3,736 shares of the company’s stock, valued at approximately $372,000.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. The Manufacturers Life Insurance Company boosted its position in shares of Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after purchasing an additional 1,690,341 shares in the last quarter. Invesco Ltd. raised its stake in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock valued at $322,887,000 after buying an additional 517,683 shares during the last quarter. Wellington Management Group LLP boosted its holdings in Moderna by 9.3% in the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock worth $579,572,000 after acquiring an additional 476,201 shares in the last quarter. Bamco Inc. NY grew its stake in shares of Moderna by 4,863.6% in the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock worth $44,091,000 after acquiring an additional 418,269 shares during the last quarter. Finally, abrdn plc increased its holdings in shares of Moderna by 477.5% during the fourth quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after acquiring an additional 399,843 shares in the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insiders Place Their Bets

In other news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares in the company, valued at approximately $224,827,186.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Moderna news, President Stephen Hoge sold 2,388 shares of Moderna stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $94.57, for a total value of $225,833.16. Following the sale, the president now directly owns 1,515,898 shares in the company, valued at approximately $143,358,473.86. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The disclosure for this sale can be found here. Insiders sold a total of 139,954 shares of company stock worth $14,822,576 over the last three months. 15.20% of the stock is currently owned by company insiders.

Moderna Stock Down 2.3 %

MRNA opened at $122.13 on Tuesday. Moderna, Inc. has a 1-year low of $62.55 and a 1-year high of $142.79. The firm’s 50 day simple moving average is $105.61 and its two-hundred day simple moving average is $94.76. The company has a current ratio of 4.03, a quick ratio of 3.91 and a debt-to-equity ratio of 0.04. The company has a market capitalization of $46.81 billion, a PE ratio of -7.79 and a beta of 1.57.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The business’s quarterly revenue was down 91.0% on a year-over-year basis. During the same period in the previous year, the firm earned $0.19 EPS. As a group, equities analysts forecast that Moderna, Inc. will post -7.47 EPS for the current year.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of analyst reports. Royal Bank of Canada raised their price objective on shares of Moderna from $125.00 to $135.00 and gave the company an “outperform” rating in a research note on Friday. William Blair restated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Oppenheimer increased their target price on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a research note on Friday. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Thursday, May 2nd. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $125.00 price target on shares of Moderna in a report on Tuesday, April 9th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $129.55.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.